Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

This study tests a combination of apatinib (a targeted drug that cuts off blood supply to tumors) and albumin-bound paclitaxel (a form of chemotherapy) for women with advanced triple-negative breast cancer — a type that lacks hormone receptors and does not respond to many targeted therapies. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have advanced triple-negative breast cancer confirmed by biopsy (HER2-negative, estrogen receptor-negative, progesterone receptor-negative) - You have measurable or evaluable disease on scans - Your overall health is adequate for chemotherapy **You may NOT be eligible if...** - You do not have triple-negative breast cancer - You have significant heart problems, uncontrolled high blood pressure, or severe bleeding risk - You are pregnant or breastfeeding - You have other serious medical conditions that make participation unsafe Talk to your doctor to see if this trial is right for you.